CYTOSORBENTS CORPORATION Revenues
CYTOSORBENTS CORPORATION (CTSO) reported Revenues of $6.23 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2019-08-06
- CYTOSORBENTS CORPORATION revenues for the quarter ending 2019-06-30 was $6.23M, a 8.29% increase year-over-year.
- CYTOSORBENTS CORPORATION revenues for the quarter ending 2019-03-31 was $5.19M, a 5.42% increase year-over-year.
- CYTOSORBENTS CORPORATION revenues for the quarter ending 2018-12-31 was $6.08M, a 30.86% increase year-over-year.
- CYTOSORBENTS CORPORATION revenues for the quarter ending 2018-09-30 was $5.74M, a 50.17% increase year-over-year.
- CYTOSORBENTS CORPORATION revenues for fiscal 2018 was $22.50M, a 48.53% increase from fiscal 2017.
- CYTOSORBENTS CORPORATION revenues for fiscal 2017 was $15.15M, a 59.02% increase from fiscal 2016.
- CYTOSORBENTS CORPORATION revenues for fiscal 2016 was $9.53M.
- CYTOSORBENTS CORPORATION revenues for fiscal 2011 was $36.08K.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 179 month | Revenues 182 month | Revenues 185 month |
|---|---|---|---|---|---|---|---|---|
| 2019-06-30 | $6.23M 10-Q · filed 2019-08-06 | $11.42M 10-Q · filed 2019-08-06 | $17.50M derived: sum of 3 quarters · filed 2019-08-06 | $23.25M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2019-03-31 | $5.19M 10-Q · filed 2019-05-07 | $11.27M derived: sum of 2 quarters · filed 2019-05-07 | $17.02M derived: sum of 3 quarters · filed 2019-05-07 | $22.77M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-12-31 | $6.08M 10-K · filed 2019-03-07 | $11.82M derived: sum of 2 quarters · filed 2019-03-07 | $17.58M derived: sum of 3 quarters · filed 2019-08-06 | $22.50M 10-K · filed 2019-03-07 | ||||
| 2018-09-30 | $5.74M 10-K · filed 2019-03-07 | $5.74M 10-Q · filed 2018-11-06 | $11.50M derived: sum of 2 quarters · filed 2019-08-06 | $16.42M 10-Q · filed 2018-11-06 | $21.07M derived: sum of 4 quarters · filed 2019-08-06 | |||
| 2018-06-30 | $5.76M 10-Q · filed 2019-08-06 | $10.68M 10-Q · filed 2019-08-06 | $15.33M derived: sum of 3 quarters · filed 2019-08-06 | $19.15M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | $4.92M 10-Q · filed 2019-05-07 | $9.57M derived: sum of 2 quarters · filed 2019-05-07 | $13.40M derived: sum of 3 quarters · filed 2019-05-07 | $16.96M derived: sum of 4 quarters · filed 2019-05-07 | ||||
| 2017-12-31 | $4.65M 10-K · filed 2019-03-07 | $8.47M derived: sum of 2 quarters · filed 2019-03-07 | $12.04M derived: sum of 3 quarters · filed 2019-03-07 | $15.15M 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | $3.82M 10-K · filed 2019-03-07 | $7.39M derived: sum of 2 quarters · filed 2019-03-07 | $10.50M 10-Q · filed 2018-11-06 | $13.59M derived: sum of 4 quarters · filed 2019-03-07 | ||||
| 2017-06-30 | $3.57M 10-K · filed 2019-03-07 | $6.68M 10-Q · filed 2018-08-02 | $9.76M derived: sum of 3 quarters · filed 2019-03-07 | $12.18M derived: sum of 4 quarters · filed 2019-03-07 | ||||
| 2017-03-31 | $3.11M 10-K · filed 2019-03-07 | $6.20M derived: sum of 2 quarters · filed 2019-03-07 | $8.61M derived: sum of 3 quarters · filed 2019-03-07 | $10.83M derived: sum of 4 quarters · filed 2019-03-07 | ||||
| 2016-12-31 | $3.08M 10-K · filed 2019-03-07 | $5.50M derived: sum of 2 quarters · filed 2019-03-07 | $7.72M derived: sum of 3 quarters · filed 2019-03-07 | $9.53M 10-K · filed 2019-03-07 | ||||
| 2016-09-30 | $2.41M 10-K · filed 2019-03-07 | $4.63M derived: sum of 2 quarters · filed 2019-03-07 | $6.44M derived: sum of 3 quarters · filed 2019-03-07 | |||||
| 2016-06-30 | $2.22M 10-K · filed 2019-03-07 | $4.03M derived: sum of 2 quarters · filed 2019-03-07 | ||||||
| 2016-03-31 | $1.81M 10-K · filed 2019-03-07 | |||||||
| 2012-06-30 | $33.04K 10-Q · filed 2012-08-13 | $49.94K 10-Q · filed 2012-08-13 | $86.01K 10-Q · filed 2012-08-13 | |||||
| 2012-03-31 | $16.89K 10-Q · filed 2012-05-15 | $52.97K 10-Q · filed 2012-05-15 | ||||||
| 2011-12-31 | $36.08K 10-K · filed 2012-03-30 | $36.08K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |